• Media type: E-Article
  • Title: The Registry Evaluating Functional Outcomes of Resynchronization Management (REFORM): Quality of Life and Psychological Functioning in Patients Receiving Cardiac Resynchronization Therapy
  • Contributor: FORD, JESSICA; SEARS, SAMUEL; RAMZA, BRIAN; REYNOLDS, DWIGHT W.; NGUYEN, PAUL; FEDEWA, MICHELLE; HOUSE, JOHN; KENNEDY, PAUL; THOMPSON, ROSE; MURRAY, CHRISTINA
  • Published: Wiley, 2014
  • Published in: Journal of Cardiovascular Electrophysiology
  • Extent: 43-51
  • Language: English
  • DOI: 10.1111/jce.12257
  • ISSN: 1540-8167; 1045-3873
  • Keywords: Physiology (medical) ; Cardiology and Cardiovascular Medicine
  • Abstract: <jats:sec><jats:title>QoL and Psychosocial Outcomes of CRT. Background</jats:title><jats:p>Cardiac resynchronization therapy (CRT) is a treatment for heart failure (HF) that improves cardiac, functional, and quality of life (QoL) outcomes. This study was designed to examine the effect of the addition of CRT (CRTD) to the implantable cardioverter defibrillator (ICD) on psychological functioning.</jats:p></jats:sec><jats:sec><jats:title>Methods and Results</jats:title><jats:p>Overall, 99 participants completed batteries before and 9 months after ICD or CRTD implantation in a registry of HF patients receiving device treatment in 3 US centers. Measures included validated indices of mental health (State Trait Anxiety Inventory, Patient Health Questionnaire: Depression) and generic and disease/device‐specific QoL (Medical Outcomes Study‐Short Form‐12, Kansas City Cardiomyopathy Questionnaire, Florida Patient Acceptance Survey, Florida Shock Anxiety Scale). Mixed between‐within analyses of covariance were employed to compare device groups on each outcome controlling for cardiac and demographic covariates. Clinically significant anxiety was elevated in both groups at both time points (57% CRTD at baseline, 29% CRTD 9 months, 44% ICD at baseline, 45% ICD 9 months). Clinically significant depressive symptoms were high at baseline (38% CRTD, 31% ICD), but dropped at follow‐up (16% CRTD, 7% ICD; P = 0.01). Participants with CRTD had improved mental component and disease‐specific QoL following CRT; however, CRTD patients had worse QoL, worse mental component QoL at baseline, and worse device acceptance at 9‐month follow‐up than patients with ICDs (all P &lt; 0.05).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Evidence of low QoL, psychological functioning, and device acceptance provides the impetus to increase research on well‐being of HF patients being implanted with CRTD in research and clinical work.</jats:p></jats:sec>
  • Description: <jats:sec><jats:title>QoL and Psychosocial Outcomes of CRT. Background</jats:title><jats:p>Cardiac resynchronization therapy (CRT) is a treatment for heart failure (HF) that improves cardiac, functional, and quality of life (QoL) outcomes. This study was designed to examine the effect of the addition of CRT (CRTD) to the implantable cardioverter defibrillator (ICD) on psychological functioning.</jats:p></jats:sec><jats:sec><jats:title>Methods and Results</jats:title><jats:p>Overall, 99 participants completed batteries before and 9 months after ICD or CRTD implantation in a registry of HF patients receiving device treatment in 3 US centers. Measures included validated indices of mental health (State Trait Anxiety Inventory, Patient Health Questionnaire: Depression) and generic and disease/device‐specific QoL (Medical Outcomes Study‐Short Form‐12, Kansas City Cardiomyopathy Questionnaire, Florida Patient Acceptance Survey, Florida Shock Anxiety Scale). Mixed between‐within analyses of covariance were employed to compare device groups on each outcome controlling for cardiac and demographic covariates. Clinically significant anxiety was elevated in both groups at both time points (57% CRTD at baseline, 29% CRTD 9 months, 44% ICD at baseline, 45% ICD 9 months). Clinically significant depressive symptoms were high at baseline (38% CRTD, 31% ICD), but dropped at follow‐up (16% CRTD, 7% ICD; P = 0.01). Participants with CRTD had improved mental component and disease‐specific QoL following CRT; however, CRTD patients had worse QoL, worse mental component QoL at baseline, and worse device acceptance at 9‐month follow‐up than patients with ICDs (all P &lt; 0.05).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Evidence of low QoL, psychological functioning, and device acceptance provides the impetus to increase research on well‐being of HF patients being implanted with CRTD in research and clinical work.</jats:p></jats:sec>
  • Footnote: